Clinical Trials Directory

We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.

We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.

We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.

We are doing this study to find out the highest dose of a drug called olaparib that is safe to give at
the same time as stereotactic radiosurgery (SRS). We also want to see if we can lessen the chance of having your cancer return by following the olaparib + SRS treatment with a combination of chemotherapy and a drug called durvalumab.

We are doing this study to find out if the Nectero EAST System® (the study procedure) is a safe and effective option for treating abdominal aortic aneurysms that are small to medium in size.

We are doing this study to figure out the best approaches for treating knee injuries that involve more than one ligament. There are 2 primary goals of this study. In Aim 1 of the study, we want to find out if it is better to have surgery shortly after MLKI or if it is better to delay surgery. In Aim 2 of the study, we want to find out if it is better to start physical rehabilitation shortly after surgery or if it is better to delay rehabilitation for a few weeks.

We are doing this study to find out how common it is for people who have HIV to accumulate excess fat in the liver or develop steatotic liver disease.

We are doing this study to find out if an investigational drug called XL092 (the study drug) is a safe and effective option on its own or in combination with other anticancer drugs.